Gaurav Tiwari — новинки

Extended release of solid dispersion of water soluble PHC was successively prepared by coevaporation with Eudragit RLPO in 1: 5 ratios. The sustainment of drug release was effected by drug-polymer ratio and method of preparation. The analysis by spectral techniques (FT-IR, FT-NMR) suggested possibility of hydrogen bonding. The results of DSC, XRD and SEM studies revealed the reduction in crystallinity of pure drug in solid dispersions as compared to their physical mixtures. The results of solubility studies were in accordance with the in vitro release profile and the order of sustainment of drug release was found in rank order of 0.1 N HCl (pH 1.2)< double distilled water< phosphate buffer (pH 7.4). The results of adsorption studies indicated that Eudragit RLPO had greater capacity to adsorb drug as compared to Eudragit RS100 in phosphate buffer (pH 7.4). The content homogeneity of PHC in granule was very high, as all the components in solid dispersions were dispersed and mixed on the molecule level. The dissolution of PHC, which is highly soluble in water, was markedly improved in the solid dispersions.

The study demonstrated the possibility of significantly improving the dissolution performance of MX by simultaneous complexation with cyclodextrin. The importance of proper selection of the most suitable counter ion to adequately improve the cyclodextrin - complexation efficiency has been pointed out. PVP showed a synergistic effect when used in combination with HP?-CD. Phase solubility experiments demonstrated that the ternary system with PVP (pH 5.8) exhibited a stability constant 12.9 times greater than the binary complex. The drug solubility in the presence of 50mM HP?-CD was about 6.23 times higher than that in the binary system. Results confirmed that the strong increase in the drug solubility shown by HP?-CD ternary system with PVP. Solid state demonstrated that freeze drying technique was suitable for obtaining solid homogeneous equimolar MX-HP?-CD-PVP complexes. These systems could be useful for formulating fast-dissolving drug solid dosage form able to assure rapid onset of analgesic action and improved bioavailability.

The method has also been developed for dissolution of antidiabetic drugs. Initially the solubility was determined in different dissolution media. The dissolution study of drugs was performed in 7.8 pH phosphate buffer in which these two drugs shows highest solubility. The dissolution was performed in pH 2.0 medium. The dissolution study was performed using Paddle with sinkers at 75 rpm. The amount of drugs were estimated.

The present study carried out pharmaceutical dosage and API. From above study, it is concluded that testing of solid dosage form and Active Pharmaceutical ingredient or analysis of solid dosage form and Active Pharmaceutical ingredient used to well developed function of body and work properly.By the above study both drugs are present in good conditions and formed according to pharmacopoeia. These both of drugs safe can be use to treatment of disease.

Leflunomide is a drug with limited water solubility. It exhibits four polymorphic forms I,II,III,IV. In the present study, form II polymorph was formulated using form I. Form II polymorph readily dissolves in water than does form I. The crystals of form I and II polymorph were characterized by IR, DSC, XRPD. Comparison of solubility of form I and form II was done by UV Spectrophotometer. There was a significant increase in solubility of form II. Aqueous film-coated tablets of form I and form II were prepared using the same processing parameters and compared for the rate of dissolution. Form II tablets showed a significant improvement in terms of dissolution rate, drug release and solubility.

The objective of this study was to optimize a periodontal drug delivery system containing antibacterial drugs having synergistic activity for the treatment of mixed periodontal infections. Periodontal pockets provide natural reservoir bathed by gingival crevicular fluid that is easily accessible for the insertion of a delivery device. Controlled release delivery of antimicrobials directly into periodontal pockets has received great interest and appears to hold a sound promise in periodontal therapy. Both topical drug delivery and controlled drug release have been termed as local drug delivery. It does not substitute the local instrumentation but acts as an adjunct to it. The periodic use of local drug delivery in minimizing bleeding, stabilizing attachment levels and thereby reducing probing depth, would allow better control and management of periodontal disease. Various drugs have been under investigation for more than 3 decades promising encouraging results. The rationales of using antibacterial drugs through local delivery into the periodontal pockets have been discussed.